Akebia Therapeutics (AKBA) Total Debt (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Total Debt data on file, last reported at $48.9 million in Q1 2026.

• On a quarterly basis, Total Debt rose 5.11% year-over-year to $48.9 million in Q1 2026; TTM through Mar 2026 was $48.9 million, a 5.11% increase from a year earlier, with the FY2025 full-year figure at $48.2 million, up 24.7% from the prior year.
• Total Debt for Q1 2026 stood at $48.9 million, up from $48.2 million in the prior quarter.
• Over the last five years, Total Debt for AKBA reached as high as $196.3 million in Q2 2022 and fell as low as $30.1 million in Q1 2024.
• Historically, Total Debt has averaged $61.5 million across 5 years, with a median of $47.1 million in 2025.
• Across the five-year window, Total Debt jumped 102.56% in 2022 and tumbled 78.36% in 2023, its largest moves.
• Year by year, Total Debt stood at $66.1 million in 2022, then tumbled by 47.51% to $34.7 million in 2023, then increased by 11.56% to $38.7 million in 2024, then advanced by 24.7% to $48.2 million in 2025, then increased by 1.33% to $48.9 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $48.9 million in Q1 2026, $48.2 million in Q4 2025, and $47.6 million in Q3 2025.